Results 131 to 140 of about 35,256 (161)
Some of the next articles are maybe not open access.
Monoclonal Anti-CD20 (B-Cell) Antibody and Autoimmune Diseases
2018Autoimmune diseases (AIDs) are a heterogeneous group of conditions with diverse clinical manifestations and complex pathogenesis. Steroids and immunosuppressants are always the cornerstone of treatment of the severe form of most AIDs, but biologic therapies have become a new weapon in the treatment.
openaire +1 more source
[Rituximab, a chimeric mouse-human anti-CD20 monoclonal antibody].
Nihon rinsho. Japanese journal of clinical medicine, 2002CD20 antigen is expressed on nearly all human B-cells and B-lymphoma cells. Rituximab is a chimeric anti-CD20 monoclonal antibody with mouse variable and human constant regions. The toxicities of rituximab are mainly infusion-related, non-hematological grade 1 or 2 episodes.
openaire +1 more source
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Nature Reviews Clinical Oncology, 2018Kabir A Khan, Robert S Kerbel
exaly
[Monoclonal anti-CD20 antibody therapy].
La Revue du praticien, 2004Laurence, Juhel, Philippe, Solal-Celigny
openaire +1 more source
Anti-CRISPR: discovery, mechanism and function
Nature Reviews Microbiology, 2017April Pawluk +2 more
exaly
New avenues for anti-epileptic drug discovery and development
Nature Reviews Drug Discovery, 2013Wolfgang Löscher
exaly
Anti-CD20 monoclonal antibody/bendamustine/polatuzumab vedotin
Reactions Weekly, 2020openaire +1 more source